Program

WEDNESDAY, APRIL 25th, 2012

10.00- REGISTRATION OPENS

11.00-11.30 SCNP General assembly

11.30-12.15  LUNCH 

12.30-12.35 PRESIDENT´S WELCOME
Ole A. Andreassen (Oslo)

12.35-13.15 PLENARY  LECTURE
SCNP 2012 OPENING LECTURE
Moderator: Ole A. Andreassen (Oslo)

PET studies of D1 and D2 dopamine receptor occu-pancy during antipsychotic drug
Lars Farde (Stockholm)

13.15-14.45 PLENARY SESSION 
Abuse/addiction: comorbidity with psychiatric disorders
Moderators: Jesper Ekelund (Helsinki) 

Drug addiction and reward mechanisms
Falk Kiefer (Heidelberg)

Psychotic disorders and drug abuse - update from TOP Study
Ole A. Andreassen (Oslo) 

Dopamine, alcohol and alcoholism revisited
Bo Söderpalm (Gothenburg)

14.45-15.15  COFFEE BREAK 

15.15-16.45 PLENARY SESSION 
Drug development in complex disorders
Moderators:  Jari Tiihonen (Stockholm) & Ole A. Andreassen (Oslo) 

Changes in neuroplasticity - a new and more appropriate tool for the assessment of complex therapeutic effects in psychopharmacology?
Bernt Gallhofer (Giessen) 

Augmentation strategies in schizophrenia: clinical outcomes.
Jari Tiihonen (Stockholm) 

Augmentation strategies in schizophrenia: underlying mechanisms. 
Torgny H. Svensson (Stockholm)

16.45-17.00   BREAK

17.00-17.45   PLENARY LECTURE
SCNP 2012 DEBATE LECTURE
Moderator: Ole A. Andreassen (Oslo) 

Is the questioning of the efficacy of antidepressant drugs well-founded?
Elias Eriksson (Gothenburg)

18.30-20.00 WELCOME RECEPTION 
City Hall, Copenhagen

THURSDAY, APRIL 26th, 2012

08.15-09.45  PLENARY SESSION
Drug development in psychiatry: high need - few opportunities
Moderators: Gregers Wegener (Aarhus) & Arvid Carlsson (Gothenburg)

What can we do to set it right again?
Arvid Carlsson (Gothenburg)

How to Revive Neuropsychopharmacological Inno-vation
Albert Gjedde (Copenhagen) 

CNS Research and Development. An industry perspective. 
Torsten Meldgaard Madsen (Lundbeck, Copenhagen)

09.45-10.15  COFFEE BREAK 

10.15-11.45   PLENARY SESSION
SCNP 2012 FRONTIERS SYMPOSIUM
Moderator: Gregers Wegener (Aarhus) & Carlos Zarate (Washington D.C., USA)

Glutamatergic compounds in depression: the story of ketamine
Carlos Zarate (Washington D.C., USA)

Glutamate mechanisms and hypotheses in mood disorders and anxiety
Maurizio Popoli (Milan)

11.45-13.15   SYMPOSIUM 
Antipychotics effects on the brain. Fact or fiction?
Moderators: Ole A. Andreassen (Oslo) & Birte Glenthøj (Copenhagen)

Effect of antipsychotic medication exposure on brain structure in macaque monkeys
Karl-Anton Dorph-Petersen (Aarhus)

Update on MRI findings of antipsychotics effect on brain structure
Ingrid Agartz (Oslo)

Differential effects of dopamine D2 and serotonin 5-HT2A receptor blockade on brain function and structure in 3 cohorts of initially antipsychotic-naive first-episode schizophrenia patients
Bjørn H. Ebdrup (Copenhagen)

13.15-14.00  LUNCH 

14.00-15.30  EDUCATIONAL SESSION 
Antidepressants: how do they work?
Moderators: Gregers Wegener (Aarhus) & Carlos Zarate (Washington D.C.)

Inflammatory mechanism in depression
Sophie Erhardt (Stockholm)

Antinflammatory mechanisms of antidepressants
Brian Leonard (Dublin) 

Neuroplasticity, NPY and antidepressants 
Aleksander A. Mathé (Stockholm)

15.30-16.00  COFFEE BREAK

16.00-17.30  PLENARY SESSION
Astra Zeneca SCNP YOUNG SCIENTIST SYMPOSIUM 
Moderators: Ole A. Andreassen (Oslo) and Gregers Wegener (Aarhus)

Antidepressant effects of macrophage migration inhibitory factor gene deletion
Cecilie Bay-Richter (Lund)

A randomized clinical trial of Histamine 2 receptor antagonism in treatment resistant schizophrenia
Katarina Meskanen (Helsinki)

An allosteric enhancer of M4 muscarinic acetylcholine receptor function inhibits behavioural and neurochemical effects of cocaine 
Ditte Dencker (Cpenhagen)

Dopamine transporter knock-in mice incapable of binding PDZ-domain proteins display a unique dopaminergic phenotype in vivo
Pernille Herrstedt Hansen (Copemhagen)

Potentiation of in vivo glutamate release in rat prefrontal cortex following systemic administration of a positive allosteric modulator of α4β2 nicotinic acetylcholine receptors 
Morten Grupe (Copenhagen)

Combined administration of the antidepressant drug fluoxetine and the antipsychotic drug olanzapine facilitates cortical AMPA receptor-mediated transmission
Carl Björkholm (Stockholm)

17.30-18.30 POSTER SESSION. 
Refreshments

19.00-     53rd CONGRESS DINNER. 
Carlsberg Museum

FRIDAY, APRIL 27th, 2012

09.00-09.45  PLENARY LECTURE
SCNP 2012 CLINICAL REVIEW LECTURE
Moderator: Andres Magnusson (Reykjavik)

Physical exercise in schizophrenia: Clinical and neurobiological effects
Peter Falkai (Göttingen, Germany)

09.45-10.30   PLENARY LECTURE 
SCNP 2012 SCIENTIFIC REVIEW LECTURE
Moderator: Ole A. Andreassen (Oslo)

Electroconvulsive therapy - a brief dicussion of effects and side effects
Anders Tingström (Lund)

10.30-11.00  COFFEE BREAK

11.00-12.30 PLENARY SESSION
Newer treatment in bipolar disorder 
Moderators: Tove Gunnarsson (Stockholm) & Rasmus W. Licht (Aarhus)

Experimental treatments in bipolar disorder
Heinz Grunze (Newcastle)

Atypicals in bipolar disorder
John Cookson (London)

Lamotrigine in bipolar disorder
Rasmus Licht (Aarhus)

12.30-13.15   PLENARY LECTURE 
SCNP 2012 EDUCATIONAL LECTURE
Moderator: Ole A. Andreassen (Oslo)

Evidence for antidepressants in bipolar disorder 
Kostas N. Fountoulakis  (Thessaloniki) 

13.15             CONCLUSION OF MEETING
Ole A. Andreassen (Oslo) 

13.30- LUNCH